Aptose Hanmi Acquisition Closing Delayed Pending Korean Approvals

An announcement from Aptose Biosciences ( (TSE:APS) ) is now available.

Aptose Biosciences Inc., a clinical-stage biotech developer of precision oncology drugs focused on hematologic malignancies, is advancing a pipeline of small-molecule cancer therapeutics designed for single-agent use and to boost existing regimens without overlapping toxicities. Its lead candidate, the oral kinase inhibitor TUS, has demonstrated activity in relapsed or refractory AML and is being developed in a frontline triplet combination for newly diagnosed AML.

On April 30, 2026, Aptose said the closing of its previously announced plan of arrangement under which Hanmi Pharmaceutical will acquire all remaining Aptose shares has been delayed due to pending Korean regulatory approvals. The parties still expect the deal to close, targeted for May, with Aptose shareholders other than Hanmi affiliates to receive C$2.41 per share in cash, a 28% premium to the company’s prior 30-day VWAP, underscoring a significant liquidity event and valuation uplift for investors despite timing uncertainty.

The most recent analyst rating on (TSE:APS) stock is a Hold with a C$2.41 price target. To see the full list of analyst forecasts on Aptose Biosciences stock, see the TSE:APS Stock Forecast page.

Spark’s Take on APS Stock

According to Spark, TipRanks’ AI Analyst, APS is a Neutral.

Overall score is held down primarily by weak financial performance—no revenue, ongoing losses/cash burn, and a stressed balance sheet with negative equity and rising debt. Technical indicators are comparatively better (price above major moving averages with positive MACD), providing partial support, while valuation remains unattractive due to negative earnings and no dividend.

To see Spark’s full report on APS stock, click here.

More about Aptose Biosciences

Aptose Biosciences Inc. is a clinical-stage biotechnology company focused on developing precision medicines for oncology, with an initial emphasis on hematologic cancers. Its small-molecule pipeline aims to deliver effective cancer therapies that can be used alone or in combination without overlapping toxicities, led by TUS, an oral kinase inhibitor for acute myeloid leukemia.

TUS has shown activity as both a monotherapy and in combination in relapsed or refractory AML patients, and is being advanced as part of a frontline triplet regimen in newly diagnosed AML. The company targets unmet medical needs in blood cancers, positioning itself within the competitive but high-potential market for targeted oncology therapeutics.

Average Trading Volume: 4,812

Technical Sentiment Signal: Sell

Current Market Cap: C$6.07M

For an in-depth examination of APS stock, go to TipRanks’ Overview page.